- Home
- ROIV vs EQR Comparison
ROIV vs EQR Comparison
Compare ROIV & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | EQR |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 24.3B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ROIV | EQR |
|---|---|---|
| Price | $28.12 | $60.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 13 |
| Target Price | $27.56 | ★ $69.58 |
| AVG Volume (30 Days) | ★ 4.5M | 2.1M |
| Earning Date | 02-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.66% |
| EPS Growth | N/A | ★ 8.09 |
| EPS | N/A | ★ 2.94 |
| Revenue | $29,053,000.00 | ★ $2,701,075,000.00 |
| Revenue This Year | N/A | $4.17 |
| Revenue Next Year | $594.84 | $3.10 |
| P/E Ratio | ★ N/A | $20.53 |
| Revenue Growth | N/A | ★ 4.76 |
| 52 Week Low | $8.73 | $57.57 |
| 52 Week High | $30.33 | $72.40 |
Technical Indicators
Market Signals| Indicator | ROIV | EQR |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 49.89 |
| Support Level | $26.94 | $58.62 |
| Resistance Level | $30.33 | $60.57 |
| Average True Range (ATR) | 0.95 | 1.10 |
| MACD | -0.12 | 0.15 |
| Stochastic Oscillator | 79.20 | 73.37 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.